A phase 3, open-label, multi-center, safety and efficacy study of Oakwood Laboratories' leuprolide acetate [leuprorelin] for injectable suspension 22.5 mg in patients with prostate cancer
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2013
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Oakwood Laboratories
- 06 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Mar 2008 Status changed from recruiting to in progress.
- 15 Feb 2008 New trial record.